Literature DB >> 19561495

Should diuretics always be included as initial antihypertensive management in early-stage CKD?

Julian Segura1, Luis M Ruilope.   

Abstract

PURPOSE OF REVIEW: This review focuses on the need for combined antihypertensive therapy drugs in patients with chronic kidney disease and the relevance of diuretics. RECENT
FINDINGS: Chronic kidney disease is a high-risk situation characterized by the presence of volume overload-related hypertension, micro/macroalbuminuria and other traditional and nontraditional risk factors. To achieve the blood pressure goal in these patients, combined antihypertensive therapy (including diuretics) is usually required.
SUMMARY: Extracellular volume expansion is an important, if not the most important, contributing factor to hypertension seen in chronic kidney disease. Protection against progression of renal dysfunction has two main requirements: strict blood pressure control and lowering proteinuria to values as near to normal as possible. Diuretics have been a useful tool to manage volume overload and to achieve strict blood pressure control in patients with chronic kidney disease. Albeit other blood pressure-lowering agents offer additional favorable effects independently of blood pressure changes, diuretics will continue to be used in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19561495     DOI: 10.1097/MNH.0b013e32832eb7fb

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  6 in total

Review 1.  Drug therapy in patients with chronic renal failure.

Authors:  Bertram Hartmann; David Czock; Frieder Keller
Journal:  Dtsch Arztebl Int       Date:  2010-09-17       Impact factor: 5.594

2.  Pediatrics: Extracellular volume in children with chronic kidney disease.

Authors:  Kevin V Lemley
Journal:  Nat Rev Nephrol       Date:  2011-05-24       Impact factor: 28.314

3.  Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort.

Authors:  Tamara Isakova; Cheryl A M Anderson; Mary B Leonard; Dawei Xie; Orlando M Gutiérrez; Leigh K Rosen; Jacquie Theurer; Keith Bellovich; Susan P Steigerwalt; Ignatius Tang; Amanda Hyre Anderson; Raymond R Townsend; Jiang He; Harold I Feldman; Myles Wolf
Journal:  Nephrol Dial Transplant       Date:  2011-03-07       Impact factor: 5.992

4.  Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.

Authors:  Mahboob Rahman; Charles E Ford; Jeffrey A Cutler; Barry R Davis; Linda B Piller; Paul K Whelton; Jackson T Wright; Joshua I Barzilay; Clinton D Brown; Pedro J Colon; Lawrence J Fine; Richard H Grimm; Alok K Gupta; Charles Baimbridge; L Julian Haywood; Mario A Henriquez; Ekambaram Ilamaythi; Suzanne Oparil; Richard Preston
Journal:  Clin J Am Soc Nephrol       Date:  2012-04-05       Impact factor: 8.237

5.  Hypotensive, Angiotensin Converting Enzyme (ACE) Inhibitory and Diuretic Activities of the Aqueous-methanol Extract of Ipomoea reniformis.

Authors:  Qaiser Jabeen; Naveed Aslam
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

6.  Extracellular Fluid Volume Is an Independent Determinant of Uncontrolled and Resistant Hypertension in Chronic Kidney Disease: A NephroTest Cohort Study.

Authors:  Emmanuelle Vidal-Petiot; Marie Metzger; Anne-Laure Faucon; Jean-Jacques Boffa; Jean-Philippe Haymann; Eric Thervet; Pascal Houillier; Guillaume Geri; Bénédicte Stengel; François Vrtovsnik; Martin Flamant
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.